Are Peptides Safe? What the FDA Says and How to Choose a Provider

Peptides prescribed by a physician, prepared by a licensed compounding pharmacy, and monitored with laboratory testing have a reasonable safety profile. Peptides bought online as “research chemicals” are a genuinely different product with genuinely different risks — unverified purity, uncertain dosing, no oversight, and no one watching for harm. Nearly every serious problem in this field traces to the second category.

Why this question deserves a straight answer

Peptide therapy occupies unusual regulatory territory, and patients are right to be confused. Some peptides are FDA-approved prescription medications. Some are legally compounded for individual patients. Some are sold openly online with a disclaimer that they are not for human use. All three are discussed on the internet as though they were the same thing.

They are not, and understanding the difference is the most protective thing a patient can do.

The three categories

1. Category one: FDA-approved peptide medications. Several peptides are approved drugs with completed clinical trials, established dosing, and regulated manufacturing. Tesamorelin, approved for visceral fat reduction in a specific population, and bremelanotide (PT-141), approved for hypoactive sexual desire disorder in premenopausal women, are examples. GLP-1 receptor agonists are peptide drugs as well. When these are used for indications beyond their approval, that is off-label prescribing — a routine, legal, and common part of medical practice when clinically justified.
2. Category two: compounded peptides. Compounding pharmacies prepare medications for individual patients under a prescription. Many peptides used clinically fall here. Compounding is legal and regulated, but it is not the same as FDA approval: compounded preparations are not individually FDA-reviewed for safety and efficacy. Which substances may be compounded is governed by specific rules, and those rules have tightened recently — several peptides that were widely compounded are now restricted or unavailable through legitimate pharmacies. Any physician practicing responsibly in this area tracks those changes and will tell you when something cannot currently be obtained legally.
3. Category three: “research use only” products. These are sold online, often openly, labeled not for human consumption. That label is not a technicality — it means the product was not manufactured to pharmaceutical standards, was not tested for purity or sterility, and carries no assurance that the vial contains what the label claims.

The American Medical Association has publicly cautioned patients about injectable peptides marketed through wellness and social media channels, noting that many are unregulated and carry real health risks, and that much of the supporting research is animal-based rather than human.

Five real risks of gray-market peptides

1. Contamination and sterility: Products not manufactured under sterile pharmaceutical conditions may carry bacterial contamination or endotoxin. These are being injected.
2. Dose inaccuracy: Independent testing of gray-market peptides has repeatedly found vials containing substantially more or less than labeled, degraded product, or different compounds entirely.
3. No screening for contraindications: Growth hormone peptides in a patient with an undiagnosed malignancy. Angiogenic peptides in someone with a cancer history. Immune peptides in an autoimmune patient on immunosuppressants. Nobody is checking.
4. No monitoring: IGF-1 climbing into a supraphysiologic range, glucose worsening, blood pressure drifting up — none of this announces itself. It is found on labs that self-treating patients are not drawing.
5. Interactions and masked disease: Peptides can interact with existing medications, and symptomatic improvement can obscure a condition that needed diagnosis. Fatigue treated with peptides is fatigue not being worked up.

Side effects of legitimate therapy

Under supervision, side effects are typically mild and manageable: injection-site redness or irritation; water retention, joint aching, or hand tingling with growth hormone peptides, usually indicating a dose that should be lowered; transient nausea or flushing with PT-141; flushing and chest tightness with rapid NAD+ infusion, which resolves when the rate is slowed; vivid dreams with evening-dosed GH peptides; and occasional headache during the first weeks of any protocol.

Serious adverse events in properly supervised peptide therapy are uncommon. Monitoring exists to keep it that way, which is precisely what self-treatment omits.

Eight questions to ask any peptide provider

Print these. Ask them. A good clinic will welcome them.

1. Will a physician evaluate me before prescribing, and will I see that physician for follow-up? If a nurse or coordinator selects your protocol from a menu, that is a sales process.
2. What laboratory testing do you require before starting, and how often afterward? No labs means no ability to know whether the treatment is working or harming.
3. Where are your peptides sourced? The answer must name licensed U.S. compounding pharmacies or FDA-registered outsourcing facilities. “We have a supplier” is not an answer.
4. What is the current regulatory status of what you’re recommending? Approved drug, compounded preparation, or unavailable — a competent provider knows and will say.
5. What are the contraindications and side effects? Any provider unwilling to discuss downsides is selling, not prescribing.
6. How will we know if this is working? There should be objective markers, not only how you feel.
7. What does the full cost include? Consultation, labs, and peptides are typically separate. Get all three clearly.
8. What happens if I don’t respond? The answer should involve reassessment — not simply adding more compounds.

At Patients Medical: Dr. Rashmi Gulati, MD personally evaluates every peptide patient and conducts follow-up; comprehensive laboratory testing through Labcorp or Quest precedes every protocol and tracks it; all peptides are prescribed through licensed U.S. compounding pharmacies; regulatory status is explained for anything recommended; contraindications are discussed before you decide; objective markers are defined at the outset; the initial one-hour evaluation is $600 with peptide costs additional and varying by type and amount prescribed, and follow-up fees depending on visit length and treatment provided; and if you are not responding, we reassess rather than escalate.

Seven red flags in peptide marketing

Patterns worth recognizing before you spend money.

1. Prices quoted before evaluation: A clinic advertising a fixed monthly peptide price has decided what you need before meeting you. Legitimate protocols cannot be priced in advance because they are not selected in advance.
2. Package deals and multi-month prepayment: Prepaying six months of a protocol removes the ability to stop when something is not working, which is precisely when you most need that ability.
3. No laboratory requirement: A clinic willing to prescribe growth hormone peptides without a baseline IGF-1, or immune peptides without immune markers, is not practicing medicine.
4. Guarantees: Specific promised outcomes — a weight figure, a timeline, a result — are not something honest medicine offers, because individual response varies substantially.
5. A menu you choose from: If you are selecting your own peptides from a list, the clinical judgment has been transferred to you, and you were not the one trained to exercise it.
6. Vagueness about sourcing: “Pharmaceutical grade” is a marketing phrase, not a regulatory category. The meaningful answer names licensed U.S. compounding pharmacies or FDA-registered outsourcing facilities.
7. Dismissiveness about regulation: A provider who waves away questions about FDA status, or who suggests that regulatory concerns are bureaucratic obstacles, is telling you something important about how they will handle your safety.

If you have been self-treating

A meaningful number of patients arrive already taking peptides purchased online, and they are frequently reluctant to say so — expecting a lecture.

You will not get one. What you will get is a review of exactly what you have been taking and at what dose, appropriate laboratory testing to see what it has done, an honest assessment of whether any of it should continue, and a legitimate pathway if the answer is yes. In some cases the compound was reasonable and the sourcing was the problem. In others the compound itself was inappropriate for your situation and we stop it.

The thing I most want to avoid is patients continuing unmonitored because they fear the conversation. Bring the vials, bring the labels, and let us look at it properly.

What good documentation looks like

A legitimate peptide practice generates a paper trail, and you should expect to see it.

You should receive written laboratory results with an explanation of what they show, not a verbal summary. You should have a written protocol specifying the compound, dose, route, frequency, and intended duration — not verbal instructions you are expected to remember. You should get written administration instructions if you are injecting at home, including storage and reconstitution where relevant. You should be told what is being monitored and when, with follow-up scheduled rather than left to you to initiate.

And your prescriptions should come from a named licensed pharmacy, with a label bearing your name, the compound, the dose, and the pharmacy’s identifying information — the same documentation you would expect for any other prescription. Product arriving in an unlabeled vial from an unnamed source is not a prescription, whatever the clinic calls it.

This documentation is not bureaucratic overhead. It is what allows another physician to understand and continue your care, what allows you to make informed decisions, and what distinguishes a medical practice from a retail transaction.

Who should not use peptides

Active malignancy or significant recent cancer history requires oncology coordination and is a contraindication for growth-signaling and angiogenic peptides. Pregnancy and breastfeeding are contraindications. Significant kidney or liver disease requires individualized evaluation. Proliferative diabetic retinopathy contraindicates growth hormone peptides. Untreated significant endocrine disease should be diagnosed and treated before peptides are considered. Patients on immunosuppressive therapy need specialist coordination before immune peptides.

Frequently asked questions

Q. Are peptides legal?

A. FDA-approved peptide medications are legal prescription drugs. Compounded peptides are legal when prescribed by a physician and prepared by a licensed pharmacy, subject to current compounding rules. Selling peptides for human use without approval is not legal, which is why gray-market products carry “research use only” labeling.

Q. Why can I buy peptides online if they need a prescription?

A. Sellers use the “not for human consumption” label to operate in a gray area. That labeling is a legal shield for them, not a safety assurance for you.

Q. Has the FDA banned peptides?

A. Not categorically. Compounding rules have tightened and specific substances have been restricted, changing what is legitimately available. This continues to evolve.

Q. Is it safe to keep taking a peptide I already started online?

A. Bring it in. We will review what you are taking, test appropriately, and advise honestly — including telling you if it should be stopped.

Q. Do I need labs if I feel fine?

A. Yes. The changes that matter most — IGF-1, glucose, inflammatory markers — are silent until they are not.

Want peptide therapy done properly?

Learn about peptide therapy in NYC at Patients Medical, 1148 Fifth Avenue, Suite 1B, New York, NY 10128. Call (212) 794-8800 or start with a free 10-minute introductory call.

Medical disclaimer: educational content only; not a substitute for professional medical advice, diagnosis, or treatment. Regulatory status of specific peptides changes over time. Individual results vary; certain peptides are prescribed off-label or as compounded preparations.